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doi:10.1Objective: The anatomic and physiologic constraints for pediatric cavopulmonary assist differ markedly from
adult Fontan circulations owing to smaller vessel sizes and risk of elevated pulmonary resistance. In this study,
hemodynamic and hemolysis performance of a catheter-based viscous impeller pump (VIP) to power the Fontan
circulation is assessed at a pediatric scale (15 kg) and performance range (0-30 mm Hg).
Methods: Computer simulation and mock circulation studies were conducted to assess the hydraulic perfor-
mance, acute hemodynamic response to different levels VIP support, and the potential for vena caval collapse.
Computational fluid dynamics simulations were used to estimate VIP hydraulic performance, shear rates, and
potential for hemolysis. Hemolysis was quantified in a mock loop with fresh bovine blood.
Results:AVIP augmented 4-way total cavopulmonary connection flow at pediatric scales and restored systemic
pressures and flows to biventricular values, without causing flow obstruction or suction. VIP generated flows up
to 4.1 L/min and pressure heads of up to 38 mm Hg at 11,000 rpm. Maximal shear rate was 160 Pa, predicting
low hemolysis risk. Observed hemolysis was low with plasma free hemoglobin of 11.4 mg $ dL1 $ h1.
Conclusions: AVIP will augment Fontan cavopulmonary flow in the proper pressure and flow ranges, with low
hemolysis risk under more stringent pediatric scale and physiology compared with adult scale. This technology
may be developed to simultaneously reduce systemic venous pressure and improve cardiac output after stage
2 or 3 Fontan repair. It may serve to compress surgical staging, lessening the pathophysiologic burden of repair.
(J Thorac Cardiovasc Surg 2013;145:249-57)Despite advances, palliative repair of functional single ven-
tricle remains an enigmatic challenge.1 Intractable morbid-
ities in the interim-staged palliative approach include severe
hypoxemia, ventricular hypertrophy, sudden hemodynamic
instability, and neurocognitive dysfunction. Late sequelae
have been linked to prior repair in which a shunt source
of pulmonary blood flow was used.2 Furthermore, recent
studies question the benefit of interim staging with respect
to late Fontan ventricular function and functional status.3
It would appear that a physiologic cost incurred early in re-
pair is reflected in suboptimal late functional status.
In the setting of preserved systolic ventricular function,
modest augmentation of cavopulmonary blood flow would
shift the univentricularFontan circulation toward a ‘‘biventric-
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Sattributes of more stable 2-ventricle physiology.4 Develop-
ment of a safe and reliable means to apply cavopulmonary as-
sist in younger patients as a bridge to Fontan may permit
compression of surgical staging of Fontan conversion.5 It
may ultimately obviate dependence on use of a systemic arte-
rial shunt source of pulmonary blood flow and resolve the as-
sociated hallmarks of hypoxemia, ventricular volume
overload, unstable parallel circulations, and impaired diastolic
coronary perfusion. A clinical device to accomplish this does
not currently exist.
To address these problems, we are developing an
expandable viscous impeller pump (VIP) to provide tempo-
rary cavopulmonary support.6 The VIP is a catheter-based,
biconical, vaned rotary pump that can be inserted percuta-
neously using a modified Seldinger technique and advanced
to the cavopulmonary junction via either the superior or in-
ferior vena cava and expanded (Figure 1). The biconical de-
sign of the VIP allows for simultaneous pumping of blood
from both the superior and inferior venae cavae to each of
the pulmonary arteries using only a single pump head.
The VIP is designed to fit within the cavopulmonary
junction of a pediatric patient and is stabilized inside the
cavopulmonary junction by an expandable nitinol cage.
In pediatric patients, the anatomic and physiologic con-
straints for cavopulmonary assist are more stringent than
for adults with failing Fontan circulations. Chief among
these are smaller vessel size and risk of elevated pulmonary
vascular resistance. This study was performed to assessrdiovascular Surgery c Volume 145, Number 1 249
Abbreviations and Acronyms
ASTM ¼ American Society of Testing and
Materials
CFD ¼ computational fluid dynamics
H-Q ¼ pump hydraulic performance
TCPC ¼ total cavopulmonary connection
VIP ¼ viscous impeller pump
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Sperformance feasibility of a VIP within the anatomic and
physiologic limitations of pediatric Fontan using computer
simulation, a mock circulatory system, and computational
fluid dynamic (CFD) methods.METHODS
Computer Simulation Study
A previously reported computer simulation model of the pediatric
biventricular cardiovascular system7 was modified to simulate single-
ventricle Fontan physiology of a 4-year-old (15 kg) child. The biventric-
ular computer simulation model has been used in previous studies to
develop and test physiologic control algorithms for mechanical circulatory
support devices.8-10 In brief, the computer model subdivides the Fontan
circulatory system into 2 heart valves and 8 blocks, which include
common atrium, single ventricle, pulmonary and systemic circulations,
vena cava, aorta, and coronary circulation. The volume of blood in each
block is described by a differential equation as a function of volume (V),
pressure (P), compliance (C), and resistance (R), which is an expression
for the macrosopic material balance for the block given by:
dVn
dt
¼ Finn Foutn ;
dVn
dt
¼ Vn1
Cn1Rn1
 Vn
Cn

1
Rn1
þ 1
Rn

þ Vnþ1
Cnþ1Rn
:
where dVn/dt is the rate of change of volume in block n, Fin is the blood
flow rate into the block, and Fout is the blood flow rate out of the block.
The heart rate, resistances, and compliances were modified to reproduce
hemodynamic pressure and flow waveforms of the univentricular Fontan
physiology of a 4-year-old child based on literature11-13 and clinical
guidance. A model of the VIP was integrated at the cavopulmonary
junction. Simulations were conducted to predict acute hemodynamic
responses from 0 to 3.5 L/min of VIP support in 0.25-L/min increments.
Ventricular, aortic, and cavopulmonary pressures, aortic, coronary, and
cavopulmonary flows, and ventricular volume and external work were cal-
culated. These parameters were compared with normal biventricular phys-
iologic values.
Mock Circulation Studies
Acute hemodynamic performance. Amock circulation system
consisting of a silicone ventricle, aorta, systemic and pulmonic resistances
and compliances, and a cavopulmonary junction was used to simulate the
univentricular Fontan circulation (Figure 2, A). The cavopulmonary junc-
tion is rigid with 11-mm diameter superior and inferior venae cavae and
9-mm diameter pulmonary arteries that are connected to flexible silicone
tubing. The prototype pediatric VIP measures 9.75 mm in height and 9.5
mm in diameter (expanded). Ventricular pressure, heart rate, systemic
and pulmonary resistances, and compliances were adjusted to reproduce
hemodynamic waveforms of univentricular Fontan physiology of
a 4-year-old child. Baseline hemodynamic pressure and flow data were col-
lected for the univentricular Fontan circulation (no VIP support). The VIP
was introduced at the cavopulmonary junction and data were collected at
VIP rotational speeds of 3000 to 11,000 rpm. The venae cavae were250 The Journal of Thoracic and Cardiovascular Surgpartially clamped (60%) to test for risk of vena caval collapse (negative
vena caval pressure) with the VIP operating at its maximum operational
speed of 11,000 rpm. The potential of the VIP to impede Fontan cavopul-
monary flow during pump failure was studied by stopping VIP rotation
while leaving the fully deployed device in place in the midst of the cavo-
pulmonary junction. The hemodynamic effect of off-center alignment of
the VIP along the axis of the venae cavae in the cavopulmonary junction
was studied by placing the VIP at 20%, 40%, 60%, 80%, and 100% offset
conditions along the axis of the inferior vena cava. A 20% offset implies
that the VIP was placed 20% of the radius of the pulmonary artery away
from the optimal location in the total cavopulmonary connection (TCPC)
along the axis of the inferior vena cava.
Hydraulic performance. Amock circulation consisting of a cavo-
pulmonary junction with VIP and a resistor was used to characterize hy-
draulic performance of the VIP. The VIP was operated at 3000 to 11,000
rpm and against 5 different resistances at each pump speed. Steady state
pressure head and flow rates generated by the VIP were recorded for
each operational condition and plotted (H-Q curve) to characterize hydrau-
lic performance.
Data collection and analysis. Hemodynamic data were collected
using a clinically approved good laboratory practices (GLP)-compliant
data acquisition system.14,15 All transducers were precalibrated and
postcalibrated against known standards to ensure measurement accuracy.
In hemodynamic studies, pressure and flow waveforms were used to
calculate heart rate, stroke volume, cardiac output, mean aortic pressure,
cavopulmonary pressures, left atrial pressure, and aortic and
cavopulmonary flows on a beat-to-beat basis by using the HEART pro-
gram16 developed in Matlab (MathWorks, Natick, Mass) and averaged to
obtain a single mean value. In hydraulic performance characterization stud-
ies, pressure and flow waveforms were used to calculate average pressure
head across the VIP and average flow rates.CFD Study
Fluent (ANSYS Inc, Canonsburg, Pa) was used to model and estimate
VIP shear stress as a predictor of hemolysis. The laminar solver was ap-
plied for no VIP and stationary VIP conditions. The rotating VIP cases
were solved using the transient realizable k-ε model. Blood viscosity of
3.5 cP and a density of 1060 kg/m3 were assumed. The grid was generated
using Solid Edge to create the solid model and Gambit (preprocessor for
Fluent) to generate the mesh (2 million tetrahedral elements). Motion
was modeled using the sliding mesh method. CFD analyses were per-
formed for no vena caval offset and 20% vena caval offset conditions.
The flow and the pressure head developed by the VIP were calculated to
plot the H-Q curve for the device. The maximum scalar stress was calcu-
lated as an indicator of blood damage.17Hemolysis Study
Fresh whole bovine blood (<48 hours) was used in an in vitro blood loop
to quantify VIP hemolysis (Figure 2, B). Blood was heparinized to an ac-
tivated clotting time greater than 300 seconds, and hematocrit valuewas ad-
justed to 28% 2%with plasma buffer solution. VIP was operated at 9000
rpm against a pressure head of 15 2 mmHg resulting in a flow rate of 2.2
 0.3 L/min. Total blood volume in the in vitro loop was 1 L. In vitro blood
damage was assessed by measuring plasma free hemoglobin, hematocrit,
red blood cell, white blood cell, and platelet counts before device operation
(baseline) and every hour thereafter for 6 hours. The plasma free hemoglo-
bin was quantified using a Plasma Photometer (HemoCue, Mission Viejo,
Calif). Platelet count and hematocrit were measured using CDC Mascot
(CDC Technologies, Oxford, Conn). Normalized index of hemolysis was
calculated using American Society of Testing and Materials (ASTM) stan-
dards. The hemolysis study parameters and protocols comply with Food
and Drug Administration guidelines for 510(k) submission and ASTM
standards.18,19ery c January 2013
FIGURE 1. Viscous impeller pump (VIP). A catheter-based, biconical, vaned pump which can be inserted percutaneously and advanced to the cavopul-
monary junction, expanded, and rotated. SVC, Superior vena cava; IVC, inferior vena cava.
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Computer Simulation
The unsupported Fontan circulation results in diminished
cardiac output and aortic systolic and diastolic pressures
compared with normal biventricular circulation (Table 1).
VIP support increases cardiac output, ventricular end-
diastolic pressures and volumes, and aortic systolic and di-
astolic pressures in patients with Fontan circulations
(Figure 3). One hundred–percent VIP support restored car-
diac output, ventricular end-diastolic pressures, and aortic
systolic and diastolic pressures to normal biventricular cir-
culation values. VIP support increased the ventricular end-
systolic and end-diastolic volumes from baseline Fontan
values (Figure 3, C). Significantly, the restoration of hemo-
dynamic parameters of the Fontan circulation to near nor-
mal values was achieved with only a modest shift of
pressure head (6 mm Hg) in the cavopulmonary junction
(CPPH ¼ pressure difference between the venae cavae and
proximal pulmonary arteries, Table 1, Figure 3). A simu-
lated VIP flow of 3.5 L/min is higher than the predictedThe Journal of Thoracic and Cacardiac output of 3.3 L/min owing to 0.2-L/min of retro-
grade flow (recirculation) around the VIP.
Mock Circulation
Mock circulatory system experiments demonstrate that
VIP support augments cardiac output by up to 23% and
mean common atrial pressure by up to 22mmHg at its max-
imal operational speeds. Further, VIP support increases pul-
monary arterial pressure, aortic systolic and diastolic
pressures, and ventricular end-systolic and end-diastolic
volumes. Importantly, only a modest (8 mm Hg) shift of
cavopulmonary pressure head in the direction of the single
ventricle leads to these significant improvements in hemo-
dynamic parameters of the Fontan circulation. The percent-
age increase in cardiac output and cavopulmonary pressure
head are consistent with computer simulation results (Table
2 and Figure 3, B).
No cavitation was observed at 11,000 rpm, the maximum
rotational speed for the VIP. Partial clamping (50%-60%)
of the venae cavae with the VIP at 11,000 rpm reducedrdiovascular Surgery c Volume 145, Number 1 251
FIGURE 2. A, Pediatric Fontan mock circulatory system: (1) single ven-
tricle, (2) aorta, (3) arterial compliance, (4) systemic vascular resistance,
(5) venous compliance, (6) Fontan junction with cavopulmonary assist de-
vice (VIP), (7) pulmonary resistance, and (8) pulmonary compliance ele-
ments. B, Schematic of the hemolysis test setup. VIP, Viscous impeller
pump; DAQ, data acquisition system.
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clamping (over 80%) of the venae cavae was necessary to
generate negative vena caval pressure (indicative of vena
caval collapse with the VIP operating at 11,000 rpm.TABLE 1. Simulation of cavopulmonary assist device flow for normal, Fon
Case HR (beats/min) SV (mL) CO (L/min) C
Normal 120 26.2 3.26
Fontan 110 26.0 2.83
Fontanþpartial VIP support 110 26.0 2.85
Fontanþpartial VIP support 110 26.9 2.96
Fontanþ full VIP support 110 30.3 3.30
Viscous impeller pump (VIP) support increases the Fontan circulation cavopulmonary pres
simulated VIP flow of 3.5 L/min (full support) is higher than the predicted cardiac output o
Viscous impeller pump;HR, heart rate; SV, stroke volume;CO, cardiac output;CO% increa
cavopulmonary pressure head ¼ vena cava pressurepulmonary artery pressure.
252 The Journal of Thoracic and Cardiovascular SurgSimulated VIP failure (nonrotation) reduced cardiac output
to baseline Fontan values. Improper alignment of the VIP at
the cavopulmonary junction by up to 80% of the radius of
the pulmonary arteries did not significantly affect the over-
all flow rate. However, substantial reduction (>20%) in
flow was observed when the VIP impeller was placed at
an offset that exceeded 80% of the radius of the pulmonary
arteries.
Hydraulic characterization demonstrates that the VIP is
capable of pumping up to 4.1 L/min and can pump against
a pressure head of up to 38 mm Hg (Figure 4, A). The H-Q
curves show a substantially flat performance profile, ideal
for mechanical circulatory support devices.
CFD
CFD did not predict any areas of low velocity or low
shear stress, suggesting minimal risk of blood stagnation
in the VIP. Peak velocities of 7 m/s were observed at the
vane edges, but CFD predicted low hemolysis rates with
a maximal shear stress of 160 Pa at 11,000 rpm (clinical
thresholdz 400 Pa17; Figure 4, B). A vena caval offset of
20% did not diminish average flow rates compared with
the no vena caval offset condition.
Hemolysis Testing
The plasma free hemoglobin at the beginning of the
6-hour test period was 0 mg/dL. At the end of the 6-hour
test period it was 70 mg/dL (average hemolysis
rate ¼ 11.4 mg $ dL1 $ h1; peak hemolysis rate ¼ 20
mg $ dL1 $ h1). The Normalized Index of Hemolysis, cal-
culated per ASTM standards, was 0.07 g/100 L. Hematocrit,
red and white blood cell counts, and platelet counts over the
6-hour period did not vary significantly from baseline.
DISCUSSION
Mechanical cavopulmonary assist within the TCPC pres-
ents unique anatomic and physiologic challenges that are
markedly dissimilar from any other mechanical circulatory
support application. Flow must be augmented in a highly
complex 3- or 4-axis geometry in which incoming and out-
going flows are perpendicular. The pump will provide sup-
port in a location where no ventricle will recover to assumetan circulation without, and Fontan circulation with VIP support
O% increase AoP (mm Hg) CPPH (mm Hg) VIP flow (L/min)
87.7/54.2 — 0
— 80.3/51.0 0.3 0
0.7 80.6/51.1 0.1 1.75
4.6 82.7/51.7 2.6 3.0
16.6 87.1/53.0 5.5 3.5
sure head, cardiac output, and aortic pressures to near normal biventricular values. A
f 3.3 L/min owing to retrograde flow (recirculation,0.2 L/min) around the VIP. VIP,
se, percent increase from baseline Fontan cardiac output; AoP, aortic pressure;CPPH,
ery c January 2013
FIGURE 3. A, Computer simulation model for a 4-year-old child with univentricular Fontan circulation without (left) and with (right) cavopulmonary
assist device (VIP) support. Systemic ventricular pressure (SVP, dashed), aortic pressure (AoP, solid), pulmonary artery pressure (PAP, dash-dot), and
vena caval pressure (VCP, dotted) waveforms generated by the Fontan circulation model. B, Aortic (AoP) and single ventricular pressure waveforms
(SVP) obtained from the mock circulation studies with no VIP support (left) and with 100% VIP support (right). VIP support increases ventricular end-
diastolic pressure and systolic and diastolic pressures. C, Single ventricular (SV) pressure volume loops for Fontan circulation (solid) and Fontan circulation
with cavopulmonary assist device (VIP) support (dashed) from the computer simulation show that VIP support increases the stroke volume, peak ventricular
pressures, and end-systolic and end-diastolic ventricular volumes. VIP, Viscous impeller pump; SVP, single ventricular pressure; AoP, aortic pressure; PAP,
pulmonary artery pressure; VCP, vena caval pressure; SV, single ventricular.
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vice. The ambient cavopulmonary pressures are low (10-15
mm Hg) and the ideal pump should generate a substantial
amount of flow while maintaining a low pressure head (6-
8 mm Hg) to avoid perfusion injury to the lung. However,
higher pressure heads (20-30 mm Hg) may be required
in pediatric patients with Fontan circulations who have pre-
capillary pulmonary hypertension that is unresponsive toThe Journal of Thoracic and Capharmacologic therapy. Because there is no volume reser-
voir for the pump inlet to draw from, vein collapse and cav-
itation owing to inlet suction must be avoided. Additionally,
there is no natural barrier (such as a valve) present within
the TCPC pathway to prevent recirculation around the
pump body. Significant recirculation around the pump
would reduce hydraulic efficiency and may increase the
risk of hemolysis. Finally, it is critical that therdiovascular Surgery c Volume 145, Number 1 253
FIGURE 3. (continued).
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pump deployment, weaning, pump shutoff or failure, and
after the pump is withdrawn.
Implantation of microaxial pumps in the superior and/or
inferior venae cavae has been proposed as ameans of provid-
ing cavopulmonary support.4,5 Implantation of one254 The Journal of Thoracic and Cardiovascular Surgmicroaxial pump in the superior or inferior vena cava alone
would lead to undesirable back pressure in the opposing
vena cava. Implantation of two microaxial pumps in the
superior and inferior venae cavae have significant
limitations, including: (1) need to implant two devices to
satisfactorily augment the double-inlet/double-outlet flowery c January 2013
TABLE 2. Mock circulation results for Fontan with various levels of VIP support
Case VIP speed (rpm) HR (beats/min) SV (mL) CO (L/min) CO% increase VCP (mm Hg) PAP (mm Hg) CAP (mm Hg)
Fontan baseline — 110 20.0 2.2 — 9 8 2
FontanþVIP 0 110 20.1 2.2 — 9 8 2
FontanþVIP 3000 110 20.9 2.3 4.5 9 12 3
FontanþVIP 5000 110 21.8 2.4 9.1 9 13 4
FontanþVIP 7000 110 24.1 2.65 20.4 8 16 5
FontanþVIP 9000 110 24.5 2.7 22.7 8 25 12
FontanþVIP 11,000 110 24.7 2.72 23.6 8 37 24
FontanþVIP,
VC partial clamp
11,000 110 19.1 2.1 4.5 5 24 21
The normal operating range of the pediatric viscous impeller pump (VIP) is expected to be approximately 5000 to 7000 rpm. At higher operational speeds, the VIP produces
a significant pressure head, which may only be needed in pediatric Fontan patients with relative pulmonary hypertension. Importantly, VIP stoppage does not alter the cardiac
output or cavopulmonary pressures from baseline values. VIP, Viscous impeller pump; HR, heart rate; SV, stroke volume; CO, cardiac output; CO% increase, percent increase
from baseline Fontan cardiac output; VCP, vena caval pressure; PAP, pulmonary artery pressure; CAP, common atrial pressure; VC, vena cava.
Giridharan et al Evolving Technology/Basic Sciencepattern characteristic of the TCPC, increasing the complex-
ity of implantation and explantation, and risk of failure; (2)
obstructive to flow, which significantly limits the ability to
wean support to no net contribution to Fontan flow andFIGURE 4. A, Pump hydraulic performance (H-Q). The VIP is capable of
providing flows up to 4 L/min and can pump against a pressure head of up to
40mmHg.B, Scalar shear stress contours showmaximum shear stress of 160
Pa (clinical threshold> 300 Pa), indicating low risk for hemolysis. CFD,
Computational fluid dynamic; EXP, hydraulic performance experimental.
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an inherently high risk of inlet suction owing to high rota-
tional speed; (4) any imbalance in flows between the pumps
will lead to undesirable backpressure; and (5) have a highde-
gree of complexity and very low manufacturing tolerances,
which may increase risk of mechanical failure. To avoid
these limitations, Lacour-Gayet and associates20 have pro-
posed modification of the existing Fontan junction to
a Y-shaped 3-way junction.20 Although this approach en-
ables Fontan support using a single microaxial pump, it
would require an additional major surgical procedure with
cardiopulmonary bypass to reconstruct the Fontan cavopul-
monary junction. Further, implantation of a microaxial
pump in a 3-way junction (with or without a barrier to recir-
culation) would have obstructive potential, which will com-
plicate the ability to wean cavopulmonary support and may
be catastrophic in the case of pump failure.
To overcome these limitations, we are developing a cavo-
pulmonary assist device (VIP) that is both expandable and
multidirectional, and can be implanted percutaneously.20
The biconical design of the VIP allows for a single impeller
to stabilize and augment cavopulmonary flow in 4 axes. No
reconstruction of the existing cavopulmonary junction is re-
quired. Computer simulation and mock circulation results
demonstrate that the VIP may augment cavopulmonary
flow and restore cardiac output, ventricular pressures and
volumes, and aortic pressures to normal biventricular values
with only a modest rise in cavopulmonary pressure head (6-
8 mm Hg). Importantly, these hemodynamic benefits were
observed with the VIP operating at nomimal operational
speeds (5000-7000 rpm, Table 2). Operation of the VIP at
higher rotational speeds (9000-11,000 rpm) in pediatric
Fontan patients with normal pulmonary resistance may
lead to significant increases in pulmonary artery and atrial
pressures (Table 2) without a significant increase in cardiac
output and should be avoided. However, at higher rotational
speeds (9000-11,000 rpm), the VIP produces a higher pres-
sure head and can pump against a significantly higher after-
load (30-40 mm Hg) to support Fontan patients withrdiovascular Surgery c Volume 145, Number 1 255
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algorithms to provide optimal cavopulmonary support and
ensure patient safety are currently under development.
Negative pressure and vena caval collapse are concerns,
especially in pediatric patients who have smaller vessel di-
mensions and inasmuch as there is no venous reservoir for
the pump to draw from in a TCPC. However, negative pres-
sures were not observed, even when the venae cavae were
partially clamped (60%) with the VIP operating at the max-
imum operational speed of 11,000 rpm, indicating low risk
for this pump to induce suction collapse of the thin-walled
venae cavae. Off-center placement of the VIP at the cavo-
pulmonary junction by up to 80% radius of the pulmonary
artery (40% diameter) resulted in negligible reduction in
pump flow. Thus, exact placement of the VIP at the cavopul-
monary junction, albeit ideal, is not essential. The results of
this study also indicate that the VIP is effective in augment-
ing cavopulmonary flow in the presence of moderate offset
between the left and right pulmonary arteries or vena caval
anastomoses at the cavopulmonary junction. When VIP ro-
tation is stopped, cavopulmonary flows and pressures return
to, but are no less than, baseline (no VIP in the cavopulmo-
nary junction) values, demonstrating that the VIP is not ob-
structive to Fontan cavopulmonary flow under any
circumstance. Numerical simulations confirm this finding
and demonstrate that the presence of a nonrotating VIP im-
peller will optimize cavopulmonary flow by beneficially
splitting incoming TCPC flow toward the outlets and mini-
mizing energy loss that otherwise occurs in a TCPC with no
device present.6,21 Further, no reduction in cavopulmonary
flows was observed with nominal values of vena caval
offset, indicating that the VIP may be suitable for most
Fontan patients.
CFD and hemolysis testing in themock demonstrated low
peak shear stress values and hemolysis rates for the VIP. A
plasma free hemoglobin level of 70 mg/dL with the VIP
compares favorably with plasma free hemoglobin levels ob-
tained after 6-hour in vitro hemolysis studies with clinically
approved blood pumps (plasma free hemoglobin of 80-250
mg/dL22-24). The low hemolysis levels and peak shear stress
values indicate that the VIPmay be an ideal device for short-
term (<30 days) cavopulmonary support.
This study demonstrates that a VIP pump scaled for use
in young children is capable of functioning well, from a hy-
draulic and hemodynamic standpoint, within the more rig-
orous physiologic environment of smaller vessel size and
risk of elevated pulmonary arterial pressures. With VIP sup-
port, a patient with single-ventricle Fontan construction, at
any stage of life, may be managed with near normal oxy-
genation, balanced pulmonary/systemic flow ratios, normal
cerebral perfusion, normal systemic venous pressure, nor-
mal preload, and normal cardiac output.5 Systemic transi-
tion to an unsupported univentricular Fontan circulation is
feasible within a 2-week time frame.25 Support can be256 The Journal of Thoracic and Cardiovascular Surgweaned after perioperative third spacing and fluid mobiliza-
tion are complete and lung function is optimal. The sys-
temic venous compartment will have the necessary time
for interstitial and oncotic adaptation to the pressure re-
quired to independently perfuse the lungs and maintain car-
diac output. Thus, VIP cavopulmonary support may enable
a direct transition to univentricular Fontan palliation based
on more stable 2-ventricle physiology and may limit or
eliminate the need for interim staging and enable Fontan
conversion in 1 stage.5,25,26
Limitations
Animal models of univentricular Fontan circulation that
accurately replicate Fontan hemodynamics do not exist,
making it a challenge to test the circulatory response to cav-
opulmonary assist before clinical application. Computer
simulation and mock circulation of the Fontan circulation
are representative of clinical observations from a purely he-
modynamic viewpoint and are not intended to replace the
importance and significance of in vivo models. The biven-
tricular computer simulation and mock circulation model,
modified to simulate univentricular Fontan circulation in
this study, has been validated and used in the development
and testing of several blood pumps.7-10,27-30 Although
incapable of replicating all expected clinical responses,
in vitro modeling does provide a controlled environment
to test the effects of VIP support and potential failure
modes, which is valuable in device development and is
not possible in vivo. The ventricular contractility and
heart rate were kept constant to reduce experimental
variability. Physiologically, heart rate and contractility
will increase with increasing preload in accordance with
the Frank-Starling mechanism. By extension, it is reason-
able to assume that the increase in cardiac output with
VIP support may be greater clinically owing to the Frank-
Starling response. The mock circulation system has
mechanical valves, which may create large aortic valve
pressure gradients and ringing during valve closure. The
length of tubing in the mock circulation may cause added
inertial effects. However, the inertial effects represent less
than 2% of the total power and an inertance mismatch
would not affect the results significantly. The impeller
tested was a rigid rather than expanding prototype and the
cavopulmonary junction was idealized from patient data.
The risk of infection and thrombosis with the VIP is ex-
pected to be similar to that of other catheter-based devices
(Intra-aortic balloon pump,Maquet Cardiovascular,Wayne,
NJ; and Impella 2.5 and 5.0, ABIOMED Inc, Danvers,
Mass) and may limit the period of VIP implantation to 30
days. Although the VIP augments pulmonary and systemic
flows, the pulmonary blood flow remains nonpulsatile. Gen-
eration of a pulse pressure by modulation of pump opera-
tional speed may mitigate any deleterious effects of
nonpulsatile pulmonary flows.31 Despite these limitations,ery c January 2013
Giridharan et al Evolving Technology/Basic Sciencethis study demonstrates efficacy of pediatric Fontan cavo-
pulmonary assist using a pediatric-scale VIP with minimal
risk of vena caval collapse or hemolysis.References
1. de Leval M. The Fontan circulation: What have we learned? What to expect? Pe-
diatr Cardiol. 1998;19:316-20.
2. Ashburn DA, McCrindle BW, Tchervenkov CI, Jacobs ML, Lofland GK,
Bove EL, et al. Outcomes after the Norwood operation in neonates with critical
aortic valve stenosis or aortic valve atresia. J Thorac Cardiovasc Surg. 2003;125:
1070-82.
3. Khambadkone S, Li J, de Leval MR, Cullen S, Deanfield JE, Redington AN.
Basal pulmonary vascular resistance and nitric oxide responsiveness late after
Fontan-type operation. Circulation. 2003;107:3204-8.
4. Rodefeld MD, Boyd JH, LaLone BJ, Bezrucko AJ, Potter AW, Brown JW. Cav-
opulmonary assist: circulatory support for the univentricular Fontan circulation.
Ann Thorac Surg. 2003;76:1911-6.
5. Rodefeld MD, Boyd JH, Myers CD, Presson RG, Wagner WW, Brown JW. Cav-
opulmonary assist in the neonate: an alternative strategy for single-ventricle pal-
liation. J Thorac Cardiovasc Surg. 2004;127:705-11.
6. Rodefeld MD, Coats B, Fisher T, Giridharan GA, Chen J, Brown JW, et al. Cav-
opulmonary assist for the univentricular Fontan circulation: von Karman Viscous
Impeller Pump. J Thorac Cardiovasc Surg. 2010;140:529-36.
7. Giridharan GA, Pantalos GM, Koenig SC, Mitchell M, Austin E, Gartner M. A
computer model of pediatric circulatory systems for testing pediatric assist de-
vices. ASAIO J. 2007;53:74-81.
8. Giridharan GA, Skliar M, Olsen DB, Pantalos GM. Modeling and control
of a brushless DC axial flow ventricular assist device. ASAIO J. 2002;48:
272-89.
9. Giridharan GA, Ewert DL, Pantalos GM, Gillars KJ, Litwak KN, Gray LA, et al.
Left ventricular and myocardial perfusion responses to volume unloading and
afterload reduction in a computer simulation. ASAIO J. 2004;50:512-8.
10. Giridharan GA, Koenig SC, Pantalos GM, Litwak KN, Spence PA. Predicted he-
modynamic benefits of counterpulsation therapy using a superficial surgical ap-
proach. ASAIO J. 2006;52:39-46.
11. Senzaki H, Masutani S, Kobayashi J, Kobayashi T, Sasaki N, Asano H, et al. Ven-
tricular afterload and ventricular work in Fontan circulation: comparison with
normal two-ventricle circulation and single-ventricle circulation with Blalock-
Taussig shunts. Circulation. 2002;105:2885-92.
12. Sachar GB, Fuhrman BP, Wang Y, Lucas RV Jr, Lock JE. Rest and exercise he-
modynamics after the Fontan procedure. Circulation. 1982;65:1043-8.
13. Mace L, Dervanian P, Bourriez A, Mazmanian GM, Lambert V, Losay J, et al.
Changes in venous return parameters associated with univentricular Fontan cir-
culations. Am J Physiol Heart Circ Physiol. 2000;279:H2335-43.
14. DrewGA, Koenig SC. Biomedical patient monitoring, data acquisition, and play-
back with LabVIEW. In: Olansen JB, Rosow E, eds. Virtual bio-instrumentation:
biomedical, clinical, and healthcare applications in LabVIEW. Upper Saddle
River, NJ: Prentice Hall; 2002:180-6.The Journal of Thoracic and Ca15. Koenig SC, Woolard C, Drew GD, Unger L, Gillars KJ, Ewert DL, et al. Inte-
grated data acquisition system formedical device testing and physiology research
in compliance with Good Laboratory Practices. Biomed Instrum Technol. 2004;
38:229-40.
16. Schroeder MJ, Perrault B, Ewert DL, Koenig SC. HEART: an automated beat-to-
beat cardiovascular analysis package using Matlab. Comput Biol Med. 2004;34:
371-88.
17. Blackshear P, Blackshear GL. Mechanical hemolysis. In: Skalak R, ed. Hand-
book of bioengineering. New York: McGraw-Hill; 1987:151-9.
18. ASTM International. ASTM F1841-97: Standard practice for assessment of he-
molysis in continuous flow blood pumps. West Conshohocken, PA: ASTM Inter-
national; 2005.
19. ASTM International. ASTM F1830-97: Standard practice for selection of blood
for in vitro evaluation of blood pumps. West Conshohocken, PA: ASTM Interna-
tional; 2005.
20. Lacour-Gayet FG, Lanning CJ, Stoica S,Wang R, Rech BA, Goldberg S, et al. An
artificial right ventricle for failing Fontan: in vitro and computational study. Ann
Thorac Surg. 2009;88:170-6.
21. Soerensen DD, Pekkan K, de Zelicourt D, Sharma S, Kanter K, Fogel M, et al.
Introduction of a new optimized total cavopulmonary connection. Ann Thorac
Surg. 2007;83:2182-90.
22. Giridharan GA, Sobieski MA, Ising MS, Slaughter MD, Koenig SC. Blood
trauma testing for mechanical circulatory support devices. Biomed Instrum Tech-
nol. 2011;45:334-9.
23. Svitek RG, Smith DE, Magovern JA. In vitro evaluation of the TandemHeart pe-
diatric centrifugal pump. ASAIO J. 2007;53:747-53.
24. Tamari Y, Lee-Sensiba K, Leonard EF, Parnell V, Tortolani AJ. The effects of
pressure and flow on hemolysis caused by Bio-Medicus centrifugal pumps and
roller pumps: guidelines for choosing a blood pump. J Thorac Cardiovasc
Surg. 1993;106:997-1007.
25. Myers CD, Ballman K, Riegle LE, Mattix KD, Litwak K, Rodefeld MD. Mech-
anisms of systemic adaptation to univentricular Fontan conversion. J Thorac
Cardiovasc Surg. 2010;140:850-6.
26. Rodefeld MD, Frankel SH, Giridharan GA. Cavopulmonary assist: (em)power-
ing the univentricular Fontan circulation. Semin Thorac Cardiovasc Surg Pediatr
Card Surg Annu. 2011;14:45-54.
27. Pantalos GM, Koenig SC, Gillars KJ, Giridharan GA, Ewert DL. Characteriza-
tion of an adult mock circulation for testing cardiac support devices. ASAIO J.
2004;50:37-46.
28. Giridharan GA, Pantalos GM, Koenig SC, Gillars KJ, Skliar M. Physiologic con-
trol of rotary blood pumps: an in vitro study. ASAIO J. 2004;50:403-9.
29. Litwak KN, Koenig SC, Giridharan GA, Gillars KJ, Pantalos GM. Ascending
aorta outflow graft location and pulsatile ventricular assist provide optimal hemo-
dynamic support in an adult mock circulation. Artif Organs. 2005;29:629-35.
30. Kaebnick BW,Giridharan GA, Koenig SC. Quantification of pulsatility as a func-
tion of vascular input impedance: an in-vitro study. ASAIO J. 2007;53:115-21.
31. Ising MS, Warren S, Sobieski MA, Slaughter MS, Koenig SC, Giridharan GA.
Flow modulation algorithms for a continuous flow ventricular assist device to in-
crease vascular pulsatility: a computer simulation study. Cardiovasc Eng Tech-
nol. 2011;2:90-100.rdiovascular Surgery c Volume 145, Number 1 257
E
T
/B
S
